Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Pyxis Oncology (Nasdaq: PYXS) reported first quarter 2026 results and progress for its ADC micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma.
Key updates include completed Phase 1 monotherapy dose-expansion enrollment, planned 2026 data readouts, new preclinical combination data, leadership additions, $42.5 million cash, and runway into Q4 2026.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage cancer therapeutics company, will participate in several May–June 2026 investor conferences.
Management will join fireside chats at RBC Capital Markets, Stifel Virtual Oncology Forum, and Jefferies Global Healthcare Conference, with live webcasts and replays available on the company’s investor relations website.
Pyxis Oncology (Nasdaq: PYXS) announced the appointment of Nelson Azoulay as Chief Business Officer on May 7, 2026. He brings more than 15 years of experience in corporate strategy, business development and antibody-drug conjugates (ADC).
Mr. Azoulay will lead corporate development and pursue strategic opportunities to advance MICVO, the company’s lead clinical asset. He previously served at Flagship Pioneering and ImmunoGen, and participated in ImmunoGen’s 2024 acquisition by AbbVie.
Pyxis Oncology (Nasdaq: PYXS) will present preclinical data at AACR 2026 showing a mouse analogue of MICVO (maMICVO) produced dose-dependent tumor inhibition and immune modulation in an HNSCC model and acted synergistically with anti-mouse PD-1 to improve tumor control.
According to the company, these findings support ongoing MICVO clinical development as monotherapy and combined with pembrolizumab, with a Phase 1 monotherapy update mid‑2026 and combination data expected in H2 2026.
Pyxis Oncology (Nasdaq: PYXS) completed target enrollment (~n=40) in the Phase 1 monotherapy dose expansion of MICVO in 2L+ R/M HNSCC and expects updated monotherapy data mid‑2026 and combination data in 2H26. The company reported $68.3M cash and expects runway into Q4 2026.
Full‑year 2025 results: Revenue $13.9M, R&D $73.7M, G&A $22.2M, and net loss $79.6M. Appointed Thomas Civik as Interim CEO; completed $11M upfront royalty sale for Enzeshu rights.
Pyxis Oncology (NASDAQ: PYXS) announced a leadership transition effective February 3, 2026: Thomas Civik, a long-standing board member, is appointed Interim CEO after Lara S. Sullivan, M.D., stepped down as President, CEO and CMO. The Board has launched a structured search for a permanent CEO.
The company said its clinical team will continue ongoing trials without interruption; lead program MICVO remains in Phase 1 monotherapy and Phase 1/2 combo studies with pembrolizumab.
Pyxis Oncology (Nasdaq: PYXS) said management will participate in two investor conferences in November 2025: a Guggenheim Healthcare Innovation fireside chat in Boston on November 10, 2025 at 2:30 p.m. ET and a Stifel Healthcare fireside chat in New York on November 11, 2025 at 4:00 p.m. ET.
Live webcasts and replays of both fireside chats will be available on Pyxis Oncology’s Events & Presentations page in the Investor Relations section of the company website.
Pyxis Oncology (NASDAQ: PYXS) reported preliminary Phase 1 data for micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) as of Nov 3, 2025. Key efficacy: 46% confirmed ORR and 92% DCR for MICVO monotherapy at 5.4 mg/kg (18 patients, 13 evaluable); 71% confirmed ORR and 100% DCR for MICVO + pembrolizumab (7 patients at 3.6/4.4 mg/kg).
Safety: no Grade 5 events; notable Grade ≥3 TRAEs in monotherapy (56%) and discontinuations in 28% linked to patients with high bodyweight; combination arm showed no TRAE-driven discontinuations. Company sold royalty rights for $11M and expects cash runway into Q4 2026. Updated monotherapy data expected mid-2026; combination updates expected 2H26.
Pyxis Oncology (NASDAQ: PYXS) reported 3Q25 results and a program update on Nov 3, 2025. The company ended 3Q25 with $77.7 million in cash, cash equivalents and short-term investments and expects runway into the second half of 2026. Pyxis expects to report preliminary Phase 1 clinical data for micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in 4Q25, covering monotherapy dose expansion (2L/3L arms) and combination dose escalation with KEYTRUDA under a Clinical Trial Collaboration Agreement with Merck.
Translational posters at ESMO and AACR-NCI-EORTC showed ctDNA reductions in the majority of 37 clinical samples and signals at the 5.4 mg/kg dose, supporting continued development.
Pyxis Oncology (NASDAQ: PYXS) will present translational data for micvotabart pelidotin (MICVO), a first-in-concept extracellular-cleaving ADC targeting EDB+FN, at ESMO 2025 (Oct 17-21) and AACR-NCI-EORTC Boston (Oct 22-26).
Key findings highlight a three-pronged mechanism—direct tumor cell killing, bystander killing, and immunogenic cell death—and report tumor microenvironment remodeling and immune activation. Observations included reductions in circulating tumor DNA tumor fraction in the vast majority of 37 clinical samples tested, with notable ctDNA TF decreases in HNSCC at the 5.4 mg/kg dose. Digital pathology features of stromal architecture may correlate with MICVO sensitivity.